Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SpyGlass Pharma, Inc.SGP · Entity 5034 | Director | February 09, 2026 | February 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SpyGlass Pharma, Inc.
Report date February 09, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,450 |
Reported balance
After 2026-02-09 transaction · row 1
1 source rowRow 1 · 2026-02-09 · Purchase · Acquired 20,000 · Balance 25,450 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 251,427 |
Reported balance
After 2026-02-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-09 · Purchase · Acquired 115,000 · Balance 251,427 F1: Shares held by New World Medical, Inc. (New World Medical). The Reporting Person is the Chief Executive Officer of New World Medical and as such has voting and investment control over the shares held by New World Medical. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of their pecuniary interest in the shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by New World Medical, Inc. (New World Medical). The Reporting Person is the Chief Executive Officer of New World Medical and as such has voting and investment control over the shares held by New World Medical. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of their pecuniary interest in the shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2026 Filed Feb 11, 2026 21:07 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | PurchaseCommon Stock | 115,000 | $16.00 | $1,840,000.00 |
DisclosureSEC source: 0002108044-26-000006 · form4-02112026_090215.xml · nonDerivative · entry 2 Khan Bilal Arshad · CIK 0002108044 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 251,427 F1 · ownership.nature: Shares held by New World Medical, Inc. (New World Medical). The Reporting Person is the Chief Executive Officer of New World Medical and as such has voting and investment control over the shares held by New World Medical. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of their pecuniary interest in the shares. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:07 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | PurchaseCommon Stock | 20,000 | $16.00 | $320,000.00 |
DisclosureSEC source: 0002108044-26-000006 · form4-02112026_090215.xml · nonDerivative · entry 1 Khan Bilal Arshad · CIK 0002108044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,450 Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:50 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | GrantStock Option (right to buy) · Derivative | 13,700 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0002108044-26-000004 · form4-02092026_090210.xml · derivative · entry 1 Khan Bilal Arshad · CIK 0002108044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,700 Underlying: Common Stock · 13,700 shares Expires 2036-02-05 F1 · derivative.exercise_date: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean February 5, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.